Nanoco Group — Encouraging commercial progress continues Nanoco’s trading update indicates that the business is making encouraging commercial progress since Dmitry Shashkov took over as #CEO in Oct' 2024. Nanoco $NANO 📖 Read the full report here: edisongroup.com/research/encou…

Dentsu Group — Japan performs well, international tougher #Dentsu’s Q225 performance was a little below management expectations, with conditions remaining challenging outside #Japan. dentsu 📖 Read the full report here: edisongroup.com/research/japan…

Mendus — Clinical activities on track #Mendus has reported its #Q225 results. $IMMU #OMX #IMMU 📖 Read the full report here: edisongroup.com/research/clini…

Gresham House Energy Storage Fund — Debt refinancing unlocks growth potential On 18 August 2025, Gresham House Energy Storage Fund (GRID) announced the signing of a new debt facility to refinance existing facilities. #GRID 📖 Read the full report here: edisongroup.com/research/debt-…

IntelliAM AI — Updated model reflects rapid evolution #IntelliAM AI continues to develop its #SaaS asset management user base at pace. IntelliAM AI $INT 📖 Read the full report here: edisongroup.com/research/updat…

NFON — H125 – a reminder that patience is required Investors viewing #NFON purely as a growth story might well be disappointed in its modest #Q225 top-line growth, but they would be missing other factors. NFON $NFN 📖 Read the full report here: edisongroup.com/research/h125-…

Picton Property Income — A 13.5% Q1 shareholder return Picton Property Income (PCTN) delivered a 1.9% NAV total #return in Q126, a combination of dividends (116% covered by EPRA earnings) and modest NAV #growth. #PCTN #LSE 📖 Read the full report here: edisongroup.com/research/a-13-…

Herantis Pharma — H125 results reflect Phase Ib progress Herantis Pharma has presented its H125 results, which reflect a period of steady progress. #HRTIS #OMX $HRTIS 📖 Read the full report here: edisongroup.com/research/h125-…

Mendus — Steady progress throughout Q225 Mendus’s Q225 results reflect a period of progress across the pipeline. #IMMU #OMX $IMMU 📖 Read the full report here: edisongroup.com/research/stead…

PWO Group — Focus remains on long-term growth potential In H125, PWO’s revenues and EBIT margins were lower, mainly due to weak automotive markets. #PWO #XETRA $PWO 📖 Read the full report here: edisongroup.com/research/focus…

International Airlines Group — Resilient growth International Airlines Group’s (IAG’s) H125 results show strong #profit #growth, expansion in industry-leading margins and solid shareholder returns. #IAG #LSE $IAG 📖 Read the full report here: edisongroup.com/research/resil…

Verve Group — Short-term impacts of platform unification Verve Group’s Q225 results show year-on-year growth slowing to 10% (-4% organic), from 32% (16% organic) in Q125. Verve | Let's make media better. #VRV #FRA $VRV 📖 Read the full report here: edisongroup.com/research/short…

PORR Group — Strong order growth set to continue PORR Group delivered new orders of €2,510m in Q225 (up 31% y-o-y), driven by several large transport infrastructure project wins. #POS $POS 📖 Read the full report here: edisongroup.com/research/stron…

The Platform Group — Robust revenue growth and margin delivery The Platform Group (TPG) delivered robust growth in H125 as it continues to benefit from a greater presence in more verticals. #TPG #FRA $TPG 📖 Read the full report here: edisongroup.com/research/robus…

ProCredit Holding — More cautious amid macroeconomic uncertainty ProCredit Holding (PCB) continues to make good progress in building the scale of its loan book. #PCZ #XETRA $PCZ 📖 Read the full report here: edisongroup.com/research/more-…

Oryzon Genomics — Foray into sickle cell disease Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in sickle cell disease. #ORY $ORY 📖 Read the full report here: edisongroup.com/research/foray…

Oncopeptides — Targeted oncology with commercial momentum Oncopeptides (ONCO) is a Swedish #biotech that aims to develop and commercialise therapies for difficult-to-treat #cancers, with a focus on #haematological #diseases. 📖 Read the full report here: edisongroup.com/research/targe…

Topps Tiles — Laying the groundwork for higher growth Topps Tiles’ (TPT’s) diversification into larger addressable markets with more trading brands. Topps Tiles #TPT #LSE $TPT 📖 Read the full report here: edisongroup.com/research/layin…

DUG Technology — Significant boost to order intake in H225 DUG Technology’s FY25 results confirmed that order intake stepped up in H225, with intake of $45.7m 131% higher half-on-half. DUG #DUG #ASX $DUG 📖 Read the full report here: edisongroup.com/research/signi…

Alzinova — Innovative new approach to Alzheimer's Alzinova is a Sweden-based clinical-stage #biopharmaceutical company seeking to advance treatments for Alzheimer’s #disease. Alzinova #ALZ $ALZ 📖 Read the full report here: edisongroup.com/research/innov…